NYSEARCA:GERM Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free GERM Stock Alerts $16.90 +0.43 (+2.61%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$16.62▼$16.9750-Day Range$16.34▼$18.9552-Week Range$15.67▼$21.70Volume2,830 shsAverage Volume2,104 shsMarket Capitalization$9.30 millionAssets Under Management$9.09 millionDividend Yield0.83%Net Expense Ratio0.68% Stock AnalysisStock AnalysisChartHoldingsRatingsStock AnalysisChartHoldingsRatings Get Amplify Treatments, Testing and Advancements ETF alerts: Email Address About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM)The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.Read More GERM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERM ETF News HeadlinesApril 23, 2024 | americanbankingnews.comAmplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM) Trading 1.8% Higher February 11, 2024 | thestreet.comETFMG Treatments Testing and Advancements ETFApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.December 28, 2023 | msn.comETFMG Treatments, Testing and Advancements ETF declares $0.0522 dividendAugust 25, 2023 | seekingalpha.comGERM ETFMG Treatments, Testing and Advancements ETFJune 23, 2023 | msn.comETFMG Treatments, Testing and Advancements ETF declares quarterly distribution of $0.0600April 25, 2023 | usatoday.comCutting-edge advances in cancer treatment are underway. Here are 3 that could change lives.April 11, 2023 | msn.comJP Morgan Maintains Moderna (MRNA) Neutral RecommendationApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 24, 2023 | marketwatch.comLactose Intolerance Treatment Market Growth by 2031See More Headlines Receive GERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerAmplify Fund NameAmplify Treatments, Testing and Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:GERM Inception Date6/17/2020 Fund ManagerCharles Ragauss, Qiao Duan WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkPrime Treatments, Testing and Advancements Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings57 Fund Statistics Assets Under Management$9.09 million Average Daily Volume$0.00 Discount/Premium-0.05% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest100 shs Miscellaneous Outstanding Shares550,000Beta0.87 Creation Unit50,000 Creation Fee$300.00 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Amplify Treatments, Testing and Advancements ETF ExpensesTypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.68%0.57%0.54%0.50%0.51%Other Expenses0.00%0.72%0.54%0.64%0.58%Total Expense0.68%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.76%-0.55%-0.68%-0.57%Net Expense0.68%0.59%0.60%0.58%0.58% Amplify Treatments, Testing and Advancements ETF (GERM) Holdings & ExposureTop 10 GERM HoldingsModerna(NASDAQ:MRNA)Holding Weight: 7.30%Quest Diagnostics(NYSE:DGX)Holding Weight: 6.83%BioNTech(NASDAQ:BNTX)Holding Weight: 6.48%Alnylam Pharmaceuticals(NASDAQ:ALNY)Holding Weight: 6.35%Laboratory Co. of America(NYSE:LH)Holding Weight: 6.20%ImmunityBio(NASDAQ:IBRX)Holding Weight: 4.93%Dynavax Technologies(NASDAQ:DVAX)Holding Weight: 4.01%Bio-Rad Laboratories(NYSE:BIO)Holding Weight: 3.80%QuidelOrtho(NASDAQ:QDEL)Holding Weight: 3.80%Immunocore(NASDAQ:IMCR)Holding Weight: 3.67%GERM Sector ExposureGERM Industry ExposureFull Holdings Details Similar ETFsStrive FAANG 2.0 ETFNYSEARCA:FTWOInvesco Electric Vehicle Metals Commodity Strategy No K-1 ETFNASDAQ:EVMTGlobal X Clean Water ETFNASDAQ:AQWAHorizon Kinetics Blockchain Development ETFNYSEARCA:BCDFB.A.D. EtfNYSEARCA:BAD GERM ETF - Frequently Asked Questions How have GERM shares performed in 2024? Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.56 at the start of the year. Since then, GERM stock has decreased by 13.6% and is now trading at $16.90. View the best growth stocks for 2024 here. What does GERM invest in? Amplify Treatments, Testing and Advancements ETF is a equity fund issued by Amplify. GERM focuses on theme investments and follows the Prime Treatments, Testing and Advancements Index. The fund's investments total to approximately $9.09 million assets under management. What stocks does Amplify Treatments, Testing and Advancements ETF hold? GERM invests in 57 holdings. Some of the stocks in their portfolio include Moderna (MRNA), Quest Diagnostics (DGX), BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY), Laboratory Co. of America (LH), ImmunityBio (IBRX), Dynavax Technologies (DVAX), Bio-Rad Laboratories (BIO), QuidelOrtho (QDEL) and Immunocore (IMCR). What is the management fee for Amplify Treatments, Testing and Advancements ETF? Amplify Treatments, Testing and Advancements ETF's management fee is 0.68% and has no other recorded expenses or fee waivers. The net expense ratio for GERM is 0.68%. What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amplify Treatments, Testing and Advancements ETF investors own include Village Farms International (VFF), Charlotte's Web (CWBHF), 3 Sixty Risk Solutions (PTVYF), Inovio Pharmaceuticals (INO), Moderna (MRNA), PayPal (PYPL), AbbVie (ABBV), Auxly Cannabis Group (CBWTF). How do I buy shares of Amplify Treatments, Testing and Advancements ETF? Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:GERM) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Treatments, Testing and Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.